ArticleFrontiers in oncology2026
Deep learning-radiomics-SUVmax integration from
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to develop and evaluate deep learning (DL) models of primary tumor (T) and cervical metastatic lymph nodes (CMLNs) using fluorine-18 fluorodeoxyglucose positron emission computed tomography ( Methods: A two-center retrospective cohort of 218 patients (105 SDM, 113 non-SDM) was analyzed. Three DL architectures (ResNet18, DenseNet121, EfficientNet-B0) were trained on CT-only, PET-only, and fused CT+PET images. Nine models combining DL features, radiomic features of T + CMLNs or T-only, clinical data, and SUVmax-T using Multilayer Perceptron (MLP) and Random Forest (RF) classifiers were established. Multiple MLP benchmark models were built based on separate T/N staging, clinical data, SUVmax-T and deep features for comparative analysis. Performance was assessed via accuracy, precision, recall, F1-score, and ROC-AUC. Permutation feature importance analysis identified core predictors of the optimal RF model, and the optimal hybrid model underwent external multicenter validation. Results: Dual-modal PET/CT networks surpassed single-modality models, with ResNet18 yielding the highest internal ROC-AUC of 0.804, superior to DenseNet121 (0.791) and EfficientNet-B0 (0.779). Integrating radiomic features (T), clinical parameters and SUVmax-T continuously elevated model discrimination, and the MLP hybrid model reached the peak internal ROC-AUC of 0.839 (recall = 0.747), outperforming the RF model (ROC-AUC = 0.787, recall = 0.777). Models built only on T/N staging reached an internal AUC of 0.476 and an external AUC of 0.513, while integrating deep features boosted their predictive AUC to 0.658 (internal) and 0.688 (external). External validation of the MLP hybrid model showed an ROC-AUC of 0.701 and a PR-AUC of 0.571. SUVmax-T was identified as the most important predictive feature in the RF hybrid model. Conclusion: Integrating ResNet18 (CT+PET) features with radiomic features (T), SUVmax-T and clinical data in an MLP framework yielded the highest performance, with SUVmax-T identified as an SDM predictor. Comparative benchmark analysis verified that this multimodal hybrid model achieved better discriminative performance than models relying solely on conventional T and N staging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.